BRIEF published on 12/11/2025 at 23:05, 7 days 2 hours ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 7 days 2 hours ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 7 days 2 hours ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 29 days 11 hours ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 29 days 11 hours ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 29 days 11 hours ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 1 month 5 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 1 month 5 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 1 month 5 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 2 months 8 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 12/19/2025 at 01:10, 49 minutes ago Ostrom Climate Exits Existing UPRIIS ERPA Arrangements
Published on 12/19/2025 at 01:00, 59 minutes ago Sun Peak Metals Announces Completion of Acquisition of Saudi Discovery Company SPV Limited
Published on 12/19/2025 at 00:50, 1 hour 9 minutes ago High Resolution Gravity Survey Targets Challenger Repeats
Published on 12/19/2025 at 00:00, 1 hour 59 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/18/2025 at 23:10, 2 hours 49 minutes ago Air T, Inc. Announces Closing of Regional Express Acquisition
Published on 12/18/2025 at 22:05, 3 hours 54 minutes ago Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology
Published on 12/18/2025 at 22:05, 3 hours 54 minutes ago Abivax to be Added to Nasdaq Biotechnology Index
Published on 12/18/2025 at 20:09, 5 hours 50 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 6 hours 29 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 6 hours 29 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST
Published on 12/18/2025 at 18:30, 7 hours 29 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 7 hours 29 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 8 hours 14 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 8 hours 14 minutes ago Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 8 hours 14 minutes ago Cie du Bois Sauvage : Cancellation of own shares
